Evidence map›Paper›PMID 25484053›Full record

ArticlemAbs2014

Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors.

Jérémy Loyau, Pauline Malinge, Bruno Daubeuf, Limin Shang, Greg Elson, Marie Kosco-Vilbois, Nicolas Fischer, François Rousseau

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Jérémy Loyaua NovImmune SA; Plan-les-Ouates , Switzerland.
Pauline Malinge
Bruno Daubeuf
Limin Shang
Greg Elson
Marie Kosco-Vilbois
Nicolas Fischer
François Rousseau
Light Chain Bioscience (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to treat Toll like receptor 4 (TLR4)-mediated diseases, we generated a potent antagonistic antibody directed against human TLR4, Hu 15C1. This antibody's potency can be modulated by engaging not only TLR4 but also Fcγ receptors (FcγR), a mechanism that is driven by avidity and not cell signaling. Here, using various formats of the antibody, we further dissect the relative contributions of the Fv and Fc portions of Hu 15C1, discovering that the relationship to potency of the different antibody arms is not linear. First, as could be anticipated, we observed that Hu 15C1 co-engages up to 3 receptors on the same plasma membrane, i.e., 2 TLR4 molecules (via its variable regions) and either FcγRI or FcγRIIA (via the Fc). The Kd of these interactions are in the nM range (3 nM of the Fv for TLR4 and 47 nM of the Fc for FcγRI). However, unexpectedly, neutralization experiments revealed that, due to the low level of cell surface TLR4 expression, the avidity afforded by engagement through 2 Fv arms was significantly limited. In contrast, the antibody's neutralization capacity increases by 3 logs when able to exploit Fc-FcγR interactions. Taken together, these results demonstrate an unforeseen level of contribution by FcγRs to an antibody's effectiveness when targeting a cell surface protein of relatively low abundance. These findings highlight an exploitable mechanism by which FcγR-bearing cells may be more powerfully targeted, envisioned to be broadly applicable to other reagents aimed at neutralizing cell surface targets on cells co-expressing FcγRs.

Indexed as

AnimalsAntibodies, Monoclonal, HumanizedAntibody AffinityCell Line, TumorCell MembraneCHO CellsCricetinaeCricetulusEnzyme-Linked Immunosorbent AssayHumansImmunoglobulin Fc FragmentsImmunoglobulin Variable RegionModels, ImmunologicalProtein BindingReceptors, IgGSurface Plasmon ResonanceAntibodies, Monoclonal, HumanizedImmunoglobulin Fc FragmentsImmunoglobulin Variable RegionReceptors, IgGTLR4 protein, humanToll-Like Receptor 4affinity maturationantibodyavidityDAMP, damage-associated molecular patternFc, fragment crystallizableFc gamma receptorsFcγR, Fc gamma receptorFv, fragment variableIg, immunoglobulinIL, interleukinIVIg, intravenous immunoglobulinLPS, lipopolysaccharidemAb, monoclonal antibodyPAMP, pathogen-associated molecular patternTLR4TLR, Toll-like receptor

Identifiers

PMID25484053
PMCPMC4622919
OpenAlexW1551462674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.